Weekly versus 3-weekly paclitaxel in combination with carboplatin in advanced ovarian cancer: which is the optimal adjuvant chemotherapy regimen?

The 3-weekly regimen of carboplatin and paclitaxel is the backbone of first line adjuvant chemotherapy for advanced ovarian cancer. The landmark Japanese Gynaecologic Oncology Group (JGOG) 3016 study demonstrated significant improvements in progression-free survival and overall survival with dose de...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Matilda X., Tan, David SP
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189442/
https://www.ncbi.nlm.nih.gov/pubmed/30207104
http://dx.doi.org/10.3802/jgo.2018.29.e96

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189442/
https://www.ncbi.nlm.nih.gov/pubmed/30207104
http://dx.doi.org/10.3802/jgo.2018.29.e96

Ejemplares similares